These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34148945)

  • 21. [Nab-paclitaxel use in pancreatic cancer: practical aspects and consequences in a French oncology day-care unit].
    Hubault M; Faure R; Walter T; Forestier J; Lombard-Bohas C; Pivot C
    Bull Cancer; 2015 May; 102(5):403-4. PubMed ID: 25866372
    [No Abstract]   [Full Text] [Related]  

  • 22. Neoadjuvant
    Peterson SL; Husnain M; Pollack T; Pimentel A; Loaiza-Bonilla A; Westendorf-Overley C; Ratermann K; Anthony L; Desimone P; Goel G; Kudrimoti M; Dineen S; Tzeng CD; Hosein PJ
    Anticancer Res; 2018 Jul; 38(7):4035-4039. PubMed ID: 29970528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
    Irie H; Suzuki R; Takagi T; Sugimoto M; Konno N; Sato Y; Hikichi T; Nakamura J; Hashimoto M; Ohira H
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):517-523. PubMed ID: 31691078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
    Ielpo B; Duran H; Diaz E; Fabra I; Caruso R; Ferri V; Malavé L; Hidalgo M; Alvarez R; Plaza C; Quijano Y; Vicente E
    Eur J Surg Oncol; 2016 Sep; 42(9):1394-400. PubMed ID: 26899943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
    Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
    JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma.
    Rogers JE; Mizrahi JD; Xiao L; Mohindroo C; Shroff RT; Wolff R; Varadhachary GR; Javle MM; Overman M; Fogelman DR; Raghav KPS; Pant S; McAllister F
    Cancer Med; 2020 Aug; 9(15):5406-5415. PubMed ID: 32519420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
    Young R; Mainwaring P; Clingan P; Parnis FX; Asghari G; Beale P; Aly A; Botteman M; Romano A; Ferrara S; Margunato-Debay S; Harris M
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e325-e331. PubMed ID: 29932294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Sahoo RK; Kumar L
    N Engl J Med; 2014 Jan; 370(5):478-9. PubMed ID: 24476440
    [No Abstract]   [Full Text] [Related]  

  • 29. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Saltz LB; Bach PB
    N Engl J Med; 2014 Jan; 370(5):478. PubMed ID: 24476439
    [No Abstract]   [Full Text] [Related]  

  • 30. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Von Hoff DD; Goldstein D; Renschler MF
    N Engl J Med; 2014 Jan; 370(5):479-80. PubMed ID: 24476438
    [No Abstract]   [Full Text] [Related]  

  • 31. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
    Borazanci E; Von Hoff DD
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):739-47. PubMed ID: 24882381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
    O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH
    Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study.
    Takano N; Yamada S; Hirakawa A; Yokoyama Y; Kawashima H; Maeda O; Okada T; Ohno E; Yamaguchi J; Ishikawa T; Sonohara F; Suenaga M; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Fujii T; Kodera Y
    Nagoya J Med Sci; 2019 May; 81(2):233-239. PubMed ID: 31239592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
    Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
    Bendell J; Sharma S; Patel MR; Windsor KS; Wainberg ZA; Gordon M; Chaves J; Berlin J; Brachmann CB; Zavodovskaya M; Liu J; Thai D; Bhargava P; Shah MA; Khan SA; Starodub A
    Oncologist; 2020 Nov; 25(11):954-962. PubMed ID: 32812320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.
    Casadei Gardini A; Aquilina M; Oboldi D; Lucchesi A; Carloni S; Tenti E; Burgio MA; Amadori D; Frassineti GL
    BMC Cancer; 2013 Nov; 13():542. PubMed ID: 24215543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use].
    Ferris Villanueva E; Martínez Penella M; Cerezuela Fuentes P; Guerrero Bautista R; García Márquez A; Mira Sirvent Mdel C
    Farm Hosp; 2015 May; 39(3):181-5. PubMed ID: 26005895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
    Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
    Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.
    Kunzmann V; Ramanathan RK; Goldstein D; Liu H; Ferrara S; Lu B; Renschler MF; Von Hoff DD
    Pancreas; 2017 Feb; 46(2):203-208. PubMed ID: 27841795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paraspinal radiation recall myositis after gemcitabine for pancreatic adenocarcinoma.
    Barrios-Anderson A; Radhakrishnan R; Yu E; Shimanovsky A
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33947675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.